Other Bcl-2 inhibitory agents that have been studied in cancer clinical trials include obatoclax mesylate [4], an indole-based Bcl-2 inhibitor that received orphan drug designation in the US, in 2004, for the treatment of chronic lymphocytic leukemia (Figure 1). Here, BCL2 is linked to cancer.